José García‐Laraña

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 389 citations · Full text

Medicine, Hematology, Oncology +15

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Juan José Lahuerta, María‐Victoria Mateos, Joaquín Martínez‐López et al. · Journal of Clinical Oncology · 2008 · 281 citations · Full text

Medicine, Oncology, Chemotherapy +12

Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Anna Sureda, R. Arranz, A Iriondo et al. · Journal of Clinical Oncology · 2001 · 231 citations

Medicine, Clinical Sciences, Oncology +15

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

Anna Sureda, M. Constans, A Iriondo et al. · Annals of Oncology · 2005 · 220 citations · Full text

Medicine, Hematology, Oncology +17